Ampio Pharmaceuticals (AMPE) 10-Q 14 Nov 18 2018 Q3 Quarterly report Financial data

Document And Entity Information

Document And Entity Information - shares	9 Months Ended
	Sep. 30, 2018	Nov. 12, 2018
Document Information [Line Items]
Document Type	10-Q
Amendment Flag	false
Document Period End Date	Sep. 30, 2018
Document Fiscal Year Focus	2,018
Document Fiscal Period Focus	Q3
Entity Registrant Name	Ampio Pharmaceuticals, Inc.
Entity Central Index Key	1,411,906
Current Fiscal Year End Date	--12-31
Entity Filer Category	Non-accelerated Filer
Trading Symbol	AMPE
Entity Common Stock, Shares Outstanding		106,716,516
Entity Emerging Growth Company	false
Entity Small Business	true

Balance Sheets

Balance Sheets - USD ($)	Sep. 30, 2018	Dec. 31, 2017
Current assets
Cash and cash equivalents	$ 8,672,062	$ 8,209,071
Prepaid expenses and other	512,481	233,815
Total current assets	9,184,543	8,442,886
Fixed assets, net (Note 3)	6,355,577	6,837,861
Deposits	33,856	33,856
Total assets	15,573,976	15,314,603
Current liabilities
Accounts payable and accrued expenses	1,534,259	2,785,529
Accrued compensation	130,054	1,033,261
Deferred rent - current portion	59,579	59,579
Total current liabilities	1,723,892	3,878,369
Long-term deferred rent	492,712	537,364
Warrant derivative liability	11,120,495	45,075,755
Total liabilities	13,337,099	49,491,488
Commitments and contingencies (Note 5)
Stockholders' equity
Preferred Stock, par value $0.0001; 10,000,000 shares authorized; none issued	0	0
Common Stock, par value $0.0001; 200,000,000 shares authorized; shares issued and outstanding - 106,591,516 in 2018 (unaudited) and 80,060,345 in 2017	10,659	8,006
Additional paid-in capital	174,753,998	170,803,783
Accumulated deficit	(172,527,780)	(204,988,674)
Total stockholders' equity	2,236,877	(34,176,885)
Total liabilities and stockholders' equity	$ 15,573,976	$ 15,314,603

Balance Sheets (Parenthetical)

Balance Sheets (Parenthetical) - $ / shares	Sep. 30, 2018	Dec. 31, 2017
Preferred Stock, par value	$ 0.0001	$ 0.0001
Preferred Stock, shares authorized	10,000,000	10,000,000
Preferred Stock, shares issued	0	0
Common Stock, par value	$ 0.0001	$ 0.0001
Common Stock, shares authorized	200,000,000	200,000,000
Common Stock, shares issued	106,591,516	80,060,345
Common Stock, shares outstanding	106,591,516	80,060,345

Statements of Operations

Statements of Operations - USD ($)	3 Months Ended		9 Months Ended
	Sep. 30, 2018	Sep. 30, 2017	Sep. 30, 2018	Sep. 30, 2017
Operating expenses
Research and development	$ 1,184,194	$ 1,992,825	$ 5,343,452	$ 6,659,349
Research and development - related party (Note 8)	0	0	0	323,554
General and administrative	756,104	1,113,312	3,303,315	3,878,850
Total operating expenses	1,940,298	3,106,137	8,646,767	10,861,753
Other income (expense)
Interest (expense) income	(3,190)	0	(3,190)	3,086
Derivative gain (loss)	7,744,708	(1,146,772)	41,110,851	2,092,994
Total other income (expense)	7,741,518	(1,146,772)	41,107,661	2,096,080
Net income (loss)	$ 5,801,220	$ (4,252,909)	$ 32,460,894	$ (8,765,673)
Basic and diluted net income (loss) per common share	$ 0.06	$ (0.06)	$ 0.37	$ (0.14)
Weighted average number of Ampio common shares outstanding	96,930,270	68,232,409	88,782,837	62,072,354

Statements of Stockholders' Equ

Statements of Stockholders' Equity (Deficit) - 9 months ended Sep. 30, 2018 - USD ($)	Total	Common Stock [Member]	Additional Paid-in Capital [Member]	Accumulated Deficit [Member]
Beginning Balance at Dec. 31, 2017	$ (34,176,885)	$ 8,006	$ 170,803,783	$ (204,988,674)
Beginning Balance, shares at Dec. 31, 2017		80,060,345
Common stock issued for services (unaudited)	60,000	$ 2	59,998	0
Common stock issued for services (unaudited) (Shares)		17,241
Options exercised, net (unaudited)	636,410	$ 35	636,375	0
Options exercised, net (unaudited) (Shares)		348,783
Warrants exercised, net (unaudited)	2,969,119	$ 616	2,968,503	0
Warrants exercised, net (unaudited) (Shares)		6,165,147
Stock-based compensation, net (unaudited)	287,339	$ 0	287,339	0
Common stock issued in connection with the confidentially marketed public offering, net of offering costs of $844,409 (unaudited)	0	$ 2,000	(2,000)	0
Common stock issued in connection with the confidentially marketed public offering, net of offering costs of $844,409 (unaudited) (Shares)		20,000,000
Net income (unaudited)	32,460,894	$ 0	0	32,460,894
Ending Balance (unaudited) at Sep. 30, 2018	$ 2,236,877	$ 10,659	$ 174,753,998	$ (172,527,780)
Ending Balance (unaudited) shares at Sep. 30, 2018		106,591,516

Statements of Stockholders' E_2

Statements of Stockholders' Equity (Deficit) (Parenthetical)	9 Months Ended
	Sep. 30, 2018USD ($)
Statement of Stockholders' Equity [Abstract]
Adjustments to Additional Paid in Capital, Stock Issued, Issuance Costs	$ 844,409

Statements of Cash Flows

Statements of Cash Flows - USD ($)	9 Months Ended
	Sep. 30, 2018	Sep. 30, 2017
Cash flows from operating activities
Net income (loss)	$ 32,460,894	$ (8,765,673)
Adjustments to reconcile net income (loss) to net cash used in operating activities
Stock-based compensation and warrant modification	287,339	683,195
Depreciation and amortization	968,034	910,725
Write-off of advances to stockholder	0	25,160
Amortization of prepaid research and development - related party (Note 8)	0	323,554
Common stock issued for services	60,000	60,000
Derivative gain	(41,110,851)	(2,092,994)
Changes in operating assets and liabilities
Increase in prepaid expenses and other	(278,666)	(79,884)
(Decrease) increase in accounts payable and accrued expenses	(1,251,270)	318,479
Decrease in deferred rent	(44,652)	(37,398)
Decrease in accrued compensation	(903,207)	(181,383)
Net cash used in operating activities	(9,812,379)	(8,836,219)
Cash flows used in investing activities
Purchase of fixed assets	(485,750)	(33,326)
Net cash used in investing activities	(485,750)	(33,326)
Cash flows from financing activities
Proceeds from sale of common stock related to the Equity Offering	8,000,000	6,594,148
Costs related to sale of common stock related to the Equity Offering	(844,409)	(812,288)
Proceeds from option and warrant exercises	3,605,529	0
Net cash provided by financing activities	10,761,120	5,781,860
Net change in cash and cash equivalents	462,991	(3,087,685)
Cash and cash equivalents at beginning of period	8,209,071	4,894,834
Cash and cash equivalents at end of period	8,672,062	1,807,149
Non-cash transactions:
Warrant derivative liability in connection with the confidentially marketed public offering	8,008,500	4,618,318
Warrants issued to placement agent in connection with the registered offering	$ 0	$ 369,465

Basis of Presentation

Basis of Presentation	9 Months Ended
	Sep. 30, 2018
Accounting Policies [Abstract]
Basis of Presentation	Note 1 - Basis of Presentation The accompanying unaudited financial statements have been prepared in accordance with accounting principles generally accepted in the United States (GAAP) for interim financial information and with the instructions of the Securities and Exchange Commission (SEC) on Form 10-Q and Rule 10-01 of Regulation S-X. Accordingly, they do not include all of the information and disclosures required by GAAP for complete financial statements. In the opinion of management, the financial statements include all adjustments necessary, which are of a normal and recurring nature, for the fair presentation of the financial position and of the results of operations and cash flows of Ampio Pharmaceuticals, Inc. (“Ampio” or the “Company”) for the periods presented. These financial statements should be read in conjunction with the audited financial statements and notes thereto for the year ended December 31, 2017 included in the Company’s Annual Report on Form 10-K filed with the SEC. The results of operations for the interim period shown in this report are not necessarily indicative of the results that may be expected for any other interim period or for the full year. The balance sheet at December 31, 2017 has been derived from the audited financial statements at that date but does not include all of the information and footnotes required by GAAP for complete financial statements. Ampio is a biopharmaceutical company primarily focused on developing compounds that decrease inflammation by (i) inhibiting specific pro-inflammatory compounds by affecting specific pathways at the protein expression and at the transcription level; (ii) activating specific phosphatase or depleting available phosphate needed for the inflammation process; and (iii) decreasing vascular permeability. Ampio’s activities have been primarily related to research and development and raising capital. The Company has not generated revenue to date. Adoption of Recent Accounting Pronouncements In May 2017, the FASB issued ASU 2017-09, “Compensation-Stock Compensation (Topic 718): Scope of Modification Accounting”. The amendments provide guidance on determining which changes to the terms and conditions of share-based payment awards require an entity to apply modification accounting under Topic 718. Under the new guidance, modification accounting is required only if the fair value, the vesting conditions, or the classification of the award changes as a result of the change in terms or conditions. For all entities, this standard is effective for financial statements issued for fiscal years beginning after December 15, 2017, and interim periods within those fiscal years. The Company adopted ASU 2017-09 during the first quarter of 2018 and the adoption of this guidance did not have a material impact on the Company’s financial statements. Recent Accounting Pronouncements In February 2016, the FASB issued ASU 2016-02, “Leases (Topic 842)” . The new standard establishes a right-of-use (ROU) model that requires a lessee to record a ROU asset and a lease liability on the balance sheet for all leases with terms longer than 12 months. Leases will be classified as either finance or operating, with classification affecting the pattern of expense recognition in the income statement. Lessees are required to use a modified retrospective transition approach for capital and operating leases existing at, or entered after, the beginning of the earliest comparative period presented in the financial statements, with certain practical expedients available. In July 2018, the FASB issued ASU 2018-10, “Codification Improvements to Topic 842, Leases,” to clarify how to apply certain aspects of the new lease standard. In July 2018, the FASB also issued ASU 2018-11, “Leases (Topic 842): Targeted Improvements,” In June 2018, the FASB issued ASU 2018-07, “Compensation-Stock Compensation (Topic 718): Improvements to Nonemployee Share-Based Payment Accounting” . The amendment expands the scope of Topic 718 to include share-based payment transactions for acquiring goods and services from nonemployees. Companies should apply the requirements of Topic 718 to nonemployee awards except for certain exemptions specified in the amendment. The guidance is effective for fiscal years beginning after December 15, 2018, including interim reporting periods within those fiscal years. Early adoption is permitted, but no earlier than the Company’s adoption date of ASU 2014-09 “ Revenue from Contracts with Customers (Topic 606)” . The Company does not expect the adoption of this ASU will have a significant impact on its financial statements. In July 2018, the FASB issued ASU 2018-09, “Codification Improvements” , which facilitates amendments to a variety of topics to clarify, correct errors in, or make minor improvements to the accounting standards codification. The effective date of the standard is dependent on the facts and circumstances of each amendment. Some amendments do not require transition guidance and will be effective upon the issuance of this standard. A majority of the amendments in ASU 2018-09 will be effective for fiscal years beginning after December 15, 2018. The Company does not expect the adoption of this ASU will have a significant impact on its financial statements. In August 2018, the FASB issued ASU 2018-13, “Fair Value Measurement - Disclosure Framework (Topic 820)” . The updated guidance improves the disclosure requirements on fair value measurements. The updated guidance is effective for fiscal years beginning after December 15, 2019, including interim reporting periods within those fiscal years. Early adoption is permitted for any removed or modified disclosures. The Company does not expect the adoption of this ASU will have a significant impact on its financial statements. The Company does not discuss recent pronouncements that are not anticipated to have an impact on or are unrelated to its financial condition, results of operations, cash flows or disclosures.

Going Concern

Going Concern	9 Months Ended
	Sep. 30, 2018
Organization, Consolidation and Presentation of Financial Statements [Abstract]
Going Concern	Note 2 - Going Concern As reflected in the accompanying financial statements, the Company had cash of $8.7 million as of September 30, 2018 with net income of $32.5 million for the nine months ended September 30, 2018. The net income is primarily attributable to the non-cash derivative gain of $41.1 million that was recognized, which was offset by the operating expenses of $8.6 million during the period ended September 30, 2018. The Company used net cash in operations of $9.8 million for the period ended September 30, 2018. As of September 30, 2018, the Company ended with an accumulated deficit of $172.5 million and stockholders’ equity of $2.2 million. In addition, the Company is a clinical stage biopharmaceutical company and has not generated any revenues or profits to date. These factors raise substantial doubt about the Company’s ability to continue as a going concern. During the nine months ending September 30, 2018, the Company received a total of $3.6 million from investor warrants and stock options being exercised (see Note 7). In addition, the Company raised gross proceeds of $8.0 million in a confidentially marketed public offering (see Note 6). Ampio expects that current cash resources and operating cash flows will be sufficient to sustain operations into the second quarter of 2019. The ability of the Company to continue its operations is dependent on management’s plans, which includes continuing to raise equity-based and debt financing, as well as encouraging additional warrant exercises. The Company is currently in negotiation with potential investors for financing. However, there is no assurance that the Company will be successful in raising sufficient capital. The accompanying unaudited interim financial statements have been prepared on a going concern basis, which contemplates the realization of assets and the satisfaction of liabilities in the normal course of business. These financial statements do not include any adjustments relating to the recovery of recorded assets or the classification of the liabilities that might be necessary should the Company be unable to continue as a going concern.

Fixed Assets

Fixed Assets	9 Months Ended
	Sep. 30, 2018
Property, Plant and Equipment [Abstract]
Fixed Assets	Note 3 - Fixed Assets Fixed assets are recorded at cost and, once placed in service, are depreciated on the straight-line method over their estimated useful lives. Leasehold improvements are accreted over the shorter of the estimated economic life or related lease terms. Fixed assets consist of the following: Estimated As of September 30, As of December 31, Useful Lives in Years 2018 2017 Manufacturing facility/clean room 3 - 8 $ 3,197,000 $ 2,773,000 Leasehold improvements 10 6,075,000 6,075,000 Office furniture and equipment 3 - 10 511,000 557,000 Lab equipment 5 - 8 1,095,000 1,059,000 Less accumulated depreciation and amortization (4,522,000 ) (3,626,000 ) Fixed assets, net $ 6,356,000 $ 6,838,000 Depreciation and amortization expense for the respective periods is as follows: Three Months Ended September 30, Nine Months Ended September 30, 2018 2017 2018 2017 Depreciation and amortization expense $ 347,000 $ 304,000 $ 968,000 $ 911,000

Fair Value Considerations

Fair Value Considerations	9 Months Ended
	Sep. 30, 2018
Fair Value Disclosures [Abstract]
Fair Value Considerations	Note 4 - Fair Value Considerations The Company’s financial instruments include cash and cash equivalents, accounts payable and accrued expenses, and warrant derivative liability. The carrying amounts of cash and cash equivalents and accounts payable and accrued expenses are carried at cost which approximates fair value due to the short maturity of these instruments. Warrants are recorded at estimated fair value based on a Black-Scholes warrant pricing model. The valuation policies are determined by the Chief Financial Officer and approved by the Company’s Board of Directors. Authoritative guidance defines fair value as the price that would be received to sell an asset or paid to transfer a liability (an exit price) in an orderly transaction between market participants at the measurement date. The guidance establishes a hierarchy for inputs used in measuring fair value that maximizes the use of observable inputs and minimizes the use of unobservable inputs by requiring that the most observable inputs be used when available. Observable inputs are inputs that market participants would use in pricing the asset or liability based on market data obtained from sources independent of Ampio. Unobservable inputs are inputs that reflect the Company’s assumptions of what market participants would use in pricing the asset or liability based on the best information available in the circumstances. The hierarchy is broken down into three levels based on reliability of the inputs as follows: Level 1: Inputs that reflect unadjusted quoted prices in active markets that are accessible to Ampio for identical assets or liabilities; Level 2: Inputs include quoted prices for similar assets and liabilities in active or inactive markets or that are observable for the asset or liability either directly or indirectly; and Level 3: Unobservable inputs that are supported by little or no market activity. Ampio’s assets and liabilities, which are measured at fair value, are classified in their entirety based on the lowest level of input that is significant to their fair value measurement. Ampio’s policy is to recognize transfers in and/or out of fair value hierarchy as of the date in which the event or change in circumstances caused the transfer. Ampio has consistently applied the valuation techniques discussed below in all periods presented. The following table presents Ampio’s financial assets and liabilities that were accounted for at fair value on a recurring basis as of September 30, 2018 and December 31, 2017, by level within the fair value hierarchy: Fair Value Measurements Using Level 1 Level 2 Level 3 Total September 30, 2018 LIABILITIES Warrant derivative liability $ - $ - $ 11,120,000 $ 11,120,000 December 31, 2017 LIABILITIES Warrant derivative liability $ - $ - $ 45,076,000 $ 45,076,000 The warrant derivative liability was valued using the Black-Scholes valuation methodology because that model embodies all the relevant assumptions that address the features underlying these instruments. For significant assumptions in valuing the warrant derivative liability as of September 30, 2018 and at issuance see Note 7. The following table sets forth a reconciliation of changes in the fair value of financial liabilities classified as Level 3 in the fair value hierarchy: Derivative Instruments Balance as of December 31, 2017 $ 45,076,000 Warrants issuances 8,008,000 Warrants exercises (13,925,000 ) Change in fair value (28,039,000 ) Balance as of September 30, 2018 $ 11,120,000

Commitments and Contingencies

Commitments and Contingencies	9 Months Ended
	Sep. 30, 2018
Commitments and Contingencies Disclosure [Abstract]
Commitments and Contingencies	Note 5 - Commitments and Contingencies Commitments and contingencies are described below and summarized by the following table: Remaining Total 2018 2019 2020 2021 2022 Thereafter Ampion supply agreement $ 7,650,000 $ 2,550,000 $ 2,550,000 $ 2,550,000 $ - $ - $ - Clinical research and trial obligations 327,000 277,000 50,000 - - - - Biologics License Application (BLA) consulting services 1,166,000 45,000 1,121,000 - - - - Facility lease 2,085,000 80,000 326,000 335,000 345,000 355,000 644,000 $ 11,228,000 $ 2,952,000 $ 4,047,000 $ 2,885,000 $ 345,000 $ 355,000 $ 644,000 Ampion Supply Agreement In October 2013, Ampio entered into a human serum albumin ingredient and purchase sale agreement which has a remaining commitment of $7.7 million. In November 2017, Ampio amended this agreement, which extended the contractual terms to 2020. Clinical Research and Trial Obligations In November 2017, Ampio entered into an Open Label Extension (OLE) study agreement. In August 2018, the Company canceled the OLE study. The Company will continue to incur close-out costs for the study through the beginning of fiscal 2019. As of September 30, 2018, there is an outstanding commitment of $327,000. Biologics License Application (BLA) Consulting Services In March 2018, Ampio entered into a BLA consulting services agreement, which has an outstanding commitment of $1.2 million. This contract is an open-ended contract and the Company incurs costs as sections of the BLA are completed. Facility Lease In December 2013, Ampio entered into a 125-month non-cancellable operating lease for office space and a manufacturing facility. The effective date for the lease was May 1, 2014. The initial base rent of the lease was $23,000 per month. The total base rent over the term of the lease is approximately $3.3 million, which includes rent abatements and leasehold incentives. The Company recognizes rent expense on a straight-line basis over the term of the lease. The Company recognizes deferred rent when the straight-line rent expense exceeds the actual lease payments and reduces deferred rent when the actual lease payments exceed the straight-line rent expense. Deferred rent is classified between current and long-term. Rent expense for the respective periods is as follows: Three Months Ended September 30, Nine Months Ended September 30, 2018 2017 2018 2017 Rent expense $ 65,000 $ 65,000 $ 195,000 $ 195,000

Common Stock

Common Stock	9 Months Ended
	Sep. 30, 2018
Equity [Abstract]
Common Stock	Note 6 - Common Stock Capital Stock At September 30, 2018 and December 31, 2017, Ampio had 200.0 million shares of common stock authorized with a par value of $0.0001 per share, and 10.0 million shares of preferred stock authorized with a par value of $0.0001 per share. At September 30, 2018 and December 31, 2017, Ampio had 106,591,516 and 80,060,345 shares of common stock outstanding, respectively. As of these same dates, Ampio had no preferred shares outstanding. Shelf Registration In March 2017, Ampio filed a shelf registration statement on Form S-3 with the Securities and Exchange Commission (“SEC”) to register Ampio common stock and warrants in an aggregate amount of up to $100.0 million for offerings from time to time, as well as 5.0 million shares of common stock available for sale by selling shareholders. The shelf registration was declared effective in April 2017 by the SEC. As a result of equity raises, approximately $78.7 million remained available under the Form S-3 as of September 30, 2018. This shelf registration statement on Form S-3 expires in March of 2020. Confidentially Marketed Public Offering In August 2018, the Company completed a confidentially marketed public offering. In this offering, the Company issued 20.0 million shares of its common stock and warrants to purchase up to 20.0 million shares of common stock. The common stock and warrants were sold in units, with each unit consisting of one share of common stock and a warrant to purchase one share of common stock. Each unit was sold to the investors in this offering at a negotiated price of $0.40 per unit generating gross proceeds of $8.0 million. In connection with the offering, the underwriter received a 7% commission totaling $560,000. The Company also incurred expenses related to legal, accounting, and other registration costs of $284,000. The shares and the warrants were offered and sold pursuant to the Company’s shelf registration statement on Form S-3 that was declared effective by the SEC in April 2017. The warrants have an exercise price of $0.40 per share and are exercisable immediately with a term of five years from issuance. The warrants include a provision where the warrant holder has the contractual right to request a cash exercise if the effectiveness of the registration statement is not maintained, but securities law would prevent the Company from issuing registered shares in a cash exercise. Therefore, the Company could be forced to cash settle the warrants. Based on this derivative feature, these warrants must be accounted for as a liability at fair value under Accounting Standards Codification (“ASC”) 815 “Derivatives and Hedging”. On the date of issuance, these warrants were valued at $8.0 million. The Company’s net cash proceeds from the confidentially marketed public offering totaled $7.2 million. When the additional non-cash charges of $8.0 million related to the 20.0 million warrants are offset against the net cash transaction proceeds, the non-cash charges exceeded 100% of the proceeds. Therefore, the Company is required to take the additional cost above the transaction proceeds and recognize a loss on the day it entered into the transaction. The loss on the transaction was $853,000 and this amount is included in the derivative gain on the statement of operations. Registered Direct Offering In October 2017, the Company entered into a Securities Purchase Agreement, with certain investors, pursuant to which the Company sold approximately 7.7 million shares of common stock at a price per share of $0.875. The gross proceeds from the offering were approximately $6.7 million. The costs associated with the offering were approximately $490,000. The shares were offered and sold pursuant to the Company’s shelf registration statement on Form S-3 that was declared effective by the SEC in April 2017. In June 2017, the Company completed a registered direct offering. In this offering, Ampio issued directly to multiple investors approximately 11.0 million shares of its common stock and approximately 11.0 million warrants to purchase shares of common stock. The common stock and warrants were sold in units, with each unit consisting of one share of common stock and a warrant to purchase one share of common stock. Each unit was sold to the investors in this offering at a negotiated price of $0.60 per unit generating gross proceeds of $6.6 million. In connection with the offering, the placement agent received an 8% commission totaling $533,000 and approximately 879,000 warrants with an exercise price of $0.76. The expiration date of these warrants is June 1, 2022. At issuance, these warrants had a value of $369,000 and were accounted for as equity-based warrants. The placement agent warrants provide for cashless exercise, which the placement agents may elect if there is no effective registration statement. The Company also incurred expenses related to legal, accounting, and other registration costs of $292,000. There was a participation right of 35% for any proposed or intended issuance or sale or exchange of securities being offered until the second anniversary of the closing date, which would have expired on June 2, 2019. However, in July 2018, the Company obtained the required number of waivers necessary to eliminate the participation rights from the June 2017 registered direct offering. The shares and the warrants were offered and sold pursuant to the Company’s shelf registration statement on Form S-3 that was declared effective by the SEC in April 2017. The investor warrants have an exercise price of $0.76 per share and were exercisable starting on December 7, 2017 with a term of five years from issuance. The investor warrants include a provision where the warrant holder has the contractual right to request a cash exercise if the effectiveness of the registration statement is not maintained, but securities law would prevent the Company from issuing registered shares in a cash exercise. Therefore, the Company could be forced to cash settle the warrant. Based on this derivative feature, these warrants must be accounted for as a liability at fair value under ASC 815 “Derivatives and Hedging”. On the date of issuance, these warrants were valued at $4.6 million. In September 2016, the Company completed a registered direct offering. In this offering, the Company issued directly to an institutional investor 5.0 million shares of its common stock and warrants to purchase up to 5.0 million shares of common stock. The common stock and warrants were sold in units, with each unit consisting of one share of common stock and a warrant to purchase one share of common stock. Each unit was sold to the investor in this offering at a negotiated price of $0.75 per unit generating gross proceeds of $3.75 million. In connection with the offering, the placement agent received a 6% commission totaling $225,000 and 150,000 warrants with an exercise price of $0.9375. The expiration date of these warrants is September 1, 2021. At issuance, these warrants had a value of $89,000 and were accounted for as equity-based warrants. The placement agent warrants provide for cashless exercise, which the placement agents may elect if there is no effective registration statement. The Company also incurred expenses related to legal, accounting, and other registration costs of $113,000. There was a participation right of 30% for any proposed or intended issuance or sale or exchange of securities being offered until the first anniversary of the closing date, which expired on September 1, 2017. The shares and the warrants were offered and sold pursuant to the Company’s shelf registration statement on Form S-3 which was declared effective by the SEC in January 2014. The Form S-3 expired in January of 2017 and the Company filed a new Form S-3 in April 2017. The investor warrants had an exercise price of $1.00 per share and were immediately exercisable with a term of five years from issuance. In addition, the investor warrants included a provision for an adjustment to the exercise price upon subsequent issuances of common stock by the Company at a price less than the warrant exercise price and the investor was entitled to purchase additional shares, such that the aggregate purchase price of $5.0 million for the warrant shares remained unchanged. The investor warrants also included a provision for redemption at the Black-Scholes value at the request of the holder upon a change of control. Based on these derivative features, these warrants were accounted for as a liability at fair value under ASC 480 “Distinguishing Liabilities from Equity”. On the date of issuance, these warrants were valued at $4.1 million. The Company’s net cash proceeds from the registered direct offering were $3.4 million. When the additional non-cash charges of $4.2 million related to the 5.0 million investor warrants and the 150,000 placement agent warrants were offset against the net cash transaction proceeds, this exceeded 100% of the proceeds so the Company was required to take the additional cost above the transaction proceeds and recognize a loss on the day of the transaction. The loss on the transaction was $804,000 and was included in derivative loss on the statement of operations. On March 27, 2017, the Company entered into a Waiver and Consent Letter Agreement with the investor from the September 2016 registered direct offering, amending the terms of the warrants previously issued. Under the Waiver and Consent Agreement, the investor waived the right to have the warrant exercise price reduced and the number of shares of common stock underlying the warrant increased in the event the Company secures any financing, including debt, which includes issuing or selling shares of common stock for a price per share less than the warrant exercise price. The investor also waived the prohibition on the Company’s ability to issue or sell shares of its common stock, options or convertible securities at a price which varies or may vary with the market price of the common stock or pursuant to an equity credit line or similar “at-the-market” offering. The waivers are permanent. In return, the Company agreed to reduce the exercise price of the warrants from $1.00 to $0.40 and to not issue or sell any shares of its capital stock for a period of 10 trading days following the execution of the Waiver and Consent Agreement. All other terms of the warrants remained the same. Based upon the amendment to this warrant agreement, the Company recognized a non-cash derivative gain of $1.1 million during the quarter ended March 31, 2017. Controlled Equity Offering In February 2016, Ampio entered into a Controlled Equity Offering SM No shares were sold under the Agreement during fiscal 2017 or the nine months ended September 30, 2018. Common Stock Issued for Services Ampio issued 17,241 and 62,478 shares of common stock valued at $60,000 and $60,000, respectively, for non-employee directors as part of their director fees for fiscal years 2018 and 2017, respectively.

Equity Instruments

Equity Instruments	9 Months Ended
	Sep. 30, 2018
Disclosure of Compensation Related Costs, Share-based Payments [Abstract]
Equity Instruments	Note 7 - Equity Instruments Options In 2010, Ampio shareholders approved the adoption of a stock and option award plan (the “2010 Plan”), under which shares were reserved for future issuance under restricted stock awards, options, and other equity awards. The 2010 Plan permits grants of equity awards to employees, directors and consultants. The shareholders have approved a total of 11.7 million shares reserved for issuance under the 2010 Plan. During the nine months ended September 30, 2018, the Company granted 115,000 options at a weighted average exercise price of $0.51 to an officer and five employees. Former employees and executives exercised 409,666 options with a weighted average exercise price of $2.06. The Company received $636,400 as of September 30, 2018 related to these option exercises. A total of 3,334 options were forfeited and 355,000 expired as of September 30, 2018. The following table summarizes Ampio’s stock option activity: Number of Options Weighted Average Exercise Price Weighted Average Remaining Contractual Life Aggregated Intrinsic Value Outstanding at December 31, 2017 7,247,165 $ 2.87 5.16 12,739,512 Granted 115,000 $ 0.51 - - Exercised (409,666 ) $ 2.06 - - Forfeited (3,334 ) $ 1.02 - - Expired or Cancelled (355,333 ) $ 5.09 - - Outstanding at September 30, 2018 6,593,832 $ 2.77 4.13 7,784 Exercisable at September 30, 2018 6,242,164 $ 2.88 3.89 7,411 Available for grant at September 30, 2018 3,198,478 Stock options outstanding at September 30, 2018 are summarized in the table below: Range of Exercise Prices Number of Options Outstanding Weighted Average Exercise Price Weighted Average Remaining Contractual Lives $0.48 - $2.00 3,083,554 $ 0.89 5.28 $2.01 - $5.00 2,285,278 $ 3.10 3.43 $5.01 - $8.93 1,225,000 $ 6.86 2.56 6,593,832 $ 2.77 4.13 Ampio computes the fair value for all options granted or modified using the Black-Scholes option pricing model. To calculate the fair value of the options, certain assumptions are made regarding components of the model, including the estimated fair value of the underlying common stock, risk-free interest rate, volatility, expected dividend yield and expected option life. Changes to the assumptions could cause significant adjustments to the valuation. Ampio calculates its volatility assumption using the actual changes in the market value of its stock. Ampio adopted ASU 2016-09 in fiscal 2017 and no longer estimates a forfeiture rate. Instead, forfeitures are recognized as they occur. The Company’s historical option exercises do not provide a reasonable basis to estimate an expected term due to the lack of sufficient data. Therefore, the Company estimates the expected term by using the simplified method. The simplified method calculates the expected term as the average time to vest and the contractual life of the options. The risk-free interest rate is based on the U.S. Treasury yield in effect at the time of the grant for treasury securities of similar maturity. Ampio has computed the fair value for options granted and modified during the period ended September 30, 2018, using the following assumptions: Expected volatility 100.66% - 127.60% Risk free interest rate 1.86% - 2.96% Expected term (years) 0.32 - 5.00 Dividend yield 0.0 % Stock-based compensation expense related to the fair value of stock options is included in the statements of operations as research and development expenses or general and administrative expenses as set forth in the table below. The following table summarizes stock-based compensation expense for the three and nine months ended September 30, 2018 and 2017: Three Months Ended September 30, Nine Months Ended September 30, 2018 2017 2018 2017 Research and development expenses Stock-based compensation $ 20,000 $ 179,000 $ 73,000 $ 255,000 General and administrative expenses Common stock issued for services - - 60,000 60,000 Stock-based compensation 75,000 127,000 214,000 354,000 $ 95,000 $ 306,000 $ 347,000 $ 669,000 Unrecognized expense at September 30, 2018 $ 68,000 Weighted average remaining years to vest 1.26 Warrants In connection with the August 2018 confidentially marketed public offering, Ampio issued warrants to purchase an aggregate of 20.0 million shares of common stock at an exercise price of $0.40 with a term of five years. Due to certain derivative features, these warrants are accounted for under liability accounting and are recorded at fair value each reporting period. As of September 30, 2018, these warrants had a fair value of $8.7 million. Significant assumptions as of September 30, 2018 and at issuance were as follows: September 30, 2018 At Issuance Exercise Price $ 0.40 $ 0.40 Volatility 123.7 % 121.8 % Equivalent term (years) 4.87 5.00 Risk-free interest rate 2.94 % 2.75 % Number of shares 19,950,000 20,000,000 In connection with the June 2017 registered direct offering, Ampio issued investor warrants to purchase an aggregate of approximately 11.0 million shares of common stock at an exercise price of $0.76 with a term of five years. Due to certain derivative features, these warrants are accounted for under liability accounting and are recorded at fair value each reporting period. As of September 30, 2018, these warrants had a fair value of $2.4 million. Significant assumptions as of September 30, 2018 and at issuance were as follows: September 30, 2018 At Issuance Exercise Price $ 0.76 $ 0.76 Volatility 137.2 % 94.6 % Equivalent term (years) 3.67 5.00 Risk-free interest rate 2.90 % 1.71 % Number of shares 6,093,582 10,990,245 The combined value for the warrant liability as of September 30, 2018 is $11.1 million (see Note 4). In connection with the 2016 registered direct offering, Ampio issued to an investor warrants to purchase an aggregate of 5.0 million shares of common stock at an exercise price of $1.00 with a term of five years. In March 2017, the exercise price of these warrants was reduced from $1.00 to $0.40. Due to certain derivative features, these warrants were accounted for under liability accounting and are recorded at fair value each reporting period. As of September 30, 2018, no fair value was recorded as these warrants were exercised in full during the first quarter of 2018. During the 2017 registered direct offering, Ampio issued placement agent warrants to purchase an aggregate of approximately 879,000 shares of common stock at an exercise price of $0.76 with a term of five years. These warrants were accounted for as equity-based awards (see Note 6). They were valued using the Black-Scholes methodology. During the 2016 registered direct offering, Ampio issued to the placement agent warrants to purchase an aggregate of 150,000 shares of common stock at an exercise price of $0.9375 with a term of five years. These warrants were accounted for as equity-based awards (see Note 6). They were valued using the Black-Scholes methodology. The following table summarizes Ampio’s warrant activity: Number of Warrants Weighted Average Exercise Price Weighted Average Remaining Contractual Life Outstanding at December 31, 2017 13,332,243 $ 0.73 4.01 Warrants issued 20,000,000 $ 0.40 Warrants exercised (6,200,476 ) $ 0.50 Warrants expired (498,576 ) $ 3.24 Outstanding at September 30, 2018 26,633,191 $ 0.49 4.56 During the nine months ended September 30, 2018, the Company issued 50,000 shares of common stock from the exercise of investor warrants with an exercise price of $0.40 from the 2018 confidentially marketed public offering. The Company also issued 1,511,999 shares of common stock from the exercise of investor warrants with an exercise price of $0.76 from the 2017 registered direct offering. In addition, the Company issued 4,500,000 shares of common stock from the exercise of investor warrants at an exercise price of $0.40 from the 2016 registered direct offering. After this warrant exercise, the Company no longer has outstanding $0.40 warrants from the 2016 registered direct offering. The Company has received approximately $3.0 million as of September 30, 2018 related to these investor warrant exercises. In July 2018, 138,477 103,148 In March 2017, the Company modified 498,576 of its outstanding warrants which extended the expiration until June 30, 2018. The $75,000 additional expense related to this modification was recognized in the quarter ended March 31, 2017. These warrants all expired as of June 30, 2018. In March 2017, the Company modified the five million warrants issued in conjunction with the Company’s September 2016 registered direct offering with an original strike price of $1.00 down to $0.40. The $1.1 million gain related to this modification was recognized in the quarter ended March 31, 2017 (see Note 6). As noted above, these warrants were exercised in full during the first quarter of 2018.

Related Party Transactions

Related Party Transactions	9 Months Ended
	Sep. 30, 2018
Related Party Transactions [Abstract]
Related Party Transactions	Note 8 - Related Party Transactions Sponsored Research Agreement Ampio entered into a sponsored research agreement with Trauma Research LLC, an entity controlled by Ampio’s Director and former Chief Scientific Officer (“CSO”), Dr. Bar-Or, in September 2009, which was amended seven times with the last amendment occurring in June 2017. The agreement was terminated effective July 5, 2017. The remaining prepaid of $252,000 was expensed during the quarter ended June 30, 2017. In conjunction with terminating this agreement, the Company extended the employment agreement for Dr. Bar-Or until July 2018. In July 2018, the Company extended Dr. Bar-Or’s employment agreement for an additional month. On August 29, 2018, Dr. Bar-Or notified the Company of his decision to retire from his role as CSO, effective September 30, 2018. Dr. Bar-Or will continue to serve as a member of the Board of Directors and the Scientific Advisory Board of the Company. Service Agreement In June 2017, Ampio terminated the shared services agreement with Aytu. For the nine months ended September 30, 2018 and 2017, the total shared overhead cost was $0 and $77,000, respectively.

Litigation

Litigation	9 Months Ended
	Sep. 30, 2018
Commitments and Contingencies Disclosure [Abstract]
Litigation	Note 9 - Litigation On August 25, 2018 and August 31, 2018, two purported stockholders of the Company brought putative class action lawsuits in the United States District Court for the Central District of California, Shi v. Ampio Pharmaceuticals, Inc., et al., Case No. 2:18-cv-07476-SJO-RAO, and in the United States District Court for the District of Colorado, Shaffer v. Ampio Pharmaceuticals, Inc., et al., Case No. 1:18-cv-02252-KLM (the “Securities Class Actions”). Plaintiffs in the Securities Class Actions allege that the Company and certain of its current officers violated federal securities laws by misrepresenting and/or omitting information regarding the AP-003 Phase III clinical trials of Ampion. Plaintiffs in the Securities Class Actions assert claims under Sections 10(b) and 20(a) and Rule 10b-5 under the Securities Exchange Act of 1934, as amended (the “Exchange Act”) on behalf of a putative class of purchasers of the Company’s common stock from December 14, 2017 through August 7, 2018. The Securities Class Actions seek unspecified damages, pre-judgment and post-judgment interest, and attorneys’ fees and costs. On September 10, 2018, a purported stockholder of the Company brought a derivative action in the United States District Court for the Central District of California, Cetrone v. Macaluso et al., Case No. 2:18-cv-05970-SJO-RAO (the “Cetrone Action”), alleging primarily that the directors and officers of Ampio breached their fiduciary duties because of their alleged misstatements and/or omissions regarding the AP-003 Phase III clinical trials of Ampion. On October 5, 2018, a purported stockholder of the Company brought a derivative action in the United States District Court for the District of Colorado, Theise v. Macaluso et al., 1:18-cv-02558, which closely parallels the allegations in the Cetrone Action. The Company believes these claims are without merit and intends to defend these lawsuits vigorously. The Company currently believes the likelihood of a loss contingency related to these matters is remote and, therefore, no provision for a loss contingency is required.

Subsequent Events

Subsequent Events	9 Months Ended
	Sep. 30, 2018
Subsequent Events [Abstract]
Subsequent Events	Note 10 - Subsequent Events As of November 14, 2018, the Company issued 125,000 shares of common stock from the exercise of investor warrants with an exercise price of $0.40. The Company has received $50,000 related to these warrant exercises. See Note 9 for litigation updates. Effective October 1, 2018, EKS&H LLLP (“EKS&H”), the independent registered public accounting firm for the Company combined with Plante & Moran PLLC (“Plante Moran”). As a result of this transaction, on October 1, 2018, EKS&H resigned as the independent registered public accounting firm for the Company. Concurrent with such resignation, the Company’s audit committee approved the engagement of Plante Moran as the new independent registered public accounting firm for the Company. On October 1, 2018, the Compensation Committee of the Board of Directors of the Company approved a one-time option repricing (the “Option Repricing”) where the exercise price of each Relevant Option (as defined below) was amended to reduce such exercise price to $0.75 per share, 44% above the closing price of the Company’s common stock on October 1, 2018 and 88% above the price per share of common stock sold in the Company’s recently completed public offering (not including the value of the accompanying warrants). “Relevant Options” are all outstanding stock options as of October 1, 2018 (vested or unvested) to acquire shares of the Company’s common stock that had exercise prices above $0.75 per share; provided, however, that the maximum dollar value of the repricing for any individual did not exceed $500,000 (with such value calculated by multiplying (i) the difference between the initial exercise price and $0.75 by (ii) the number of options being repriced). In conjunction with the repricing, the Compensation Committee determined to eliminate all outstanding accrued bonuses, which amount to approximately $813,000. The Compensation Committee believes that the Option Repricing is in the best interests of the Company, as the amended stock options will provide added incentives to retain and motivate key contributors of the Company at this critical juncture without incurring the stock dilution resulting from significant option grants. The Compensation Committee also believes that the repricing better aligns the interests of the key contributors with the goals of the Company. The Company’s Board of Directors, along with the Chairman and Chief Executive Officer, Michael Macaluso, did not participate in the Option Repricing. In October 2018, the Company retained a law firm to represent its interests in a lobbying effort with the Food and Drug Administration, or FDA.

Basis of Presentation (Policies

Basis of Presentation (Policies)	9 Months Ended
	Sep. 30, 2018
Accounting Policies [Abstract]
Recent Accounting Pronouncements	Adoption of Recent Accounting Pronouncements In May 2017, the FASB issued ASU 2017-09, “Compensation-Stock Compensation (Topic 718): Scope of Modification Accounting”. The amendments provide guidance on determining which changes to the terms and conditions of share-based payment awards require an entity to apply modification accounting under Topic 718. Under the new guidance, modification accounting is required only if the fair value, the vesting conditions, or the classification of the award changes as a result of the change in terms or conditions. For all entities, this standard is effective for financial statements issued for fiscal years beginning after December 15, 2017, and interim periods within those fiscal years. The Company adopted ASU 2017-09 during the first quarter of 2018 and the adoption of this guidance did not have a material impact on the Company’s financial statements. Recent Accounting Pronouncements In February 2016, the FASB issued ASU 2016-02, “Leases (Topic 842)” . The new standard establishes a right-of-use (ROU) model that requires a lessee to record a ROU asset and a lease liability on the balance sheet for all leases with terms longer than 12 months. Leases will be classified as either finance or operating, with classification affecting the pattern of expense recognition in the income statement. Lessees are required to use a modified retrospective transition approach for capital and operating leases existing at, or entered after, the beginning of the earliest comparative period presented in the financial statements, with certain practical expedients available. In July 2018, the FASB issued ASU 2018-10, “Codification Improvements to Topic 842, Leases,” to clarify how to apply certain aspects of the new lease standard. In July 2018, the FASB also issued ASU 2018-11, “Leases (Topic 842): Targeted Improvements,” In June 2018, the FASB issued ASU 2018-07, “Compensation-Stock Compensation (Topic 718): Improvements to Nonemployee Share-Based Payment Accounting” . The amendment expands the scope of Topic 718 to include share-based payment transactions for acquiring goods and services from nonemployees. Companies should apply the requirements of Topic 718 to nonemployee awards except for certain exemptions specified in the amendment. The guidance is effective for fiscal years beginning after December 15, 2018, including interim reporting periods within those fiscal years. Early adoption is permitted, but no earlier than the Company’s adoption date of ASU 2014-09 “ Revenue from Contracts with Customers (Topic 606)” . The Company does not expect the adoption of this ASU will have a significant impact on its financial statements. In July 2018, the FASB issued ASU 2018-09, “Codification Improvements” , which facilitates amendments to a variety of topics to clarify, correct errors in, or make minor improvements to the accounting standards codification. The effective date of the standard is dependent on the facts and circumstances of each amendment. Some amendments do not require transition guidance and will be effective upon the issuance of this standard. A majority of the amendments in ASU 2018-09 will be effective for fiscal years beginning after December 15, 2018. The Company does not expect the adoption of this ASU will have a significant impact on its financial statements. In August 2018, the FASB issued ASU 2018-13, “Fair Value Measurement - Disclosure Framework (Topic 820)” . The updated guidance improves the disclosure requirements on fair value measurements. The updated guidance is effective for fiscal years beginning after December 15, 2019, including interim reporting periods within those fiscal years. Early adoption is permitted for any removed or modified disclosures. The Company does not expect the adoption of this ASU will have a significant impact on its financial statements. The Company does not discuss recent pronouncements that are not anticipated to have an impact on or are unrelated to its financial condition, results of operations, cash flows or disclosures.

Fixed Assets (Tables)

Fixed Assets (Tables)	9 Months Ended
	Sep. 30, 2018
Property, Plant and Equipment [Abstract]
Schedule of Fixed Assets	Fixed assets are recorded at cost and, once placed in service, are depreciated on the straight-line method over their estimated useful lives. Leasehold improvements are accreted over the shorter of the estimated economic life or related lease terms. Fixed assets consist of the following: Estimated As of September 30, As of December 31, Useful Lives in Years 2018 2017 Manufacturing facility/clean room 3 - 8 $ 3,197,000 $ 2,773,000 Leasehold improvements 10 6,075,000 6,075,000 Office furniture and equipment 3 - 10 511,000 557,000 Lab equipment 5 - 8 1,095,000 1,059,000 Less accumulated depreciation and amortization (4,522,000 ) (3,626,000 ) Fixed assets, net $ 6,356,000 $ 6,838,000
Schedule Of Depreciation And Amortization Expense	Depreciation and amortization expense for the respective periods is as follows: Three Months Ended September 30, Nine Months Ended September 30, 2018 2017 2018 2017 Depreciation and amortization expense $ 347,000 $ 304,000 $ 968,000 $ 911,000

Fair Value Considerations (Tabl

Fair Value Considerations (Tables)	9 Months Ended
	Sep. 30, 2018
Fair Value Disclosures [Abstract]
Schedule of Fair Value, Assets and Liabilities Measured on Recurring Basis	The following table presents Ampio’s financial assets and liabilities that were accounted for at fair value on a recurring basis as of September 30, 2018 and December 31, 2017, by level within the fair value hierarchy: Fair Value Measurements Using Level 1 Level 2 Level 3 Total September 30, 2018 LIABILITIES Warrant derivative liability $ - $ - $ 11,120,000 $ 11,120,000 December 31, 2017 LIABILITIES Warrant derivative liability $ - $ - $ 45,076,000 $ 45,076,000
Fair Value, Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation	The following table sets forth a reconciliation of changes in the fair value of financial liabilities classified as Level 3 in the fair value hierarchy: Derivative Instruments Balance as of December 31, 2017 $ 45,076,000 Warrants issuances 8,008,000 Warrants exercises (13,925,000 ) Change in fair value (28,039,000 ) Balance as of September 30, 2018 $ 11,120,000

Commitments and Contingencies (

Commitments and Contingencies (Tables)	9 Months Ended
	Sep. 30, 2018
Commitments and Contingencies Disclosure [Abstract]
Summary of Commitments and Contingencies	Commitments and contingencies are described below and summarized by the following table: Remaining Total 2018 2019 2020 2021 2022 Thereafter Ampion supply agreement $ 7,650,000 $ 2,550,000 $ 2,550,000 $ 2,550,000 $ - $ - $ - Clinical research and trial obligations 327,000 277,000 50,000 - - - - Biologics License Application (BLA) consulting services 1,166,000 45,000 1,121,000 - - - - Facility lease 2,085,000 80,000 326,000 335,000 345,000 355,000 644,000 $ 11,228,000 $ 2,952,000 $ 4,047,000 $ 2,885,000 $ 345,000 $ 355,000 $ 644,000
Rent Expense	Rent expense for the respective periods is as follows: Three Months Ended September 30, Nine Months Ended September 30, 2018 2017 2018 2017 Rent expense $ 65,000 $ 65,000 $ 195,000 $ 195,000

Equity Instruments (Tables)

Equity Instruments (Tables)	9 Months Ended
	Sep. 30, 2018
Stock Option Activity	The following table summarizes Ampio’s stock option activity: Number of Options Weighted Average Exercise Price Weighted Average Remaining Contractual Life Aggregated Intrinsic Value Outstanding at December 31, 2017 7,247,165 $ 2.87 5.16 12,739,512 Granted 115,000 $ 0.51 - - Exercised (409,666 ) $ 2.06 - - Forfeited (3,334 ) $ 1.02 - - Expired or Cancelled (355,333 ) $ 5.09 - - Outstanding at September 30, 2018 6,593,832 $ 2.77 4.13 7,784 Exercisable at September 30, 2018 6,242,164 $ 2.88 3.89 7,411 Available for grant at September 30, 2018 3,198,478
Summary of Stock Options Outstanding and Exercisable	Stock options outstanding at September 30, 2018 are summarized in the table below: Range of Exercise Prices Number of Options Outstanding Weighted Average Exercise Price Weighted Average Remaining Contractual Lives $0.48 - $2.00 3,083,554 $ 0.89 5.28 $2.01 - $5.00 2,285,278 $ 3.10 3.43 $5.01 - $8.93 1,225,000 $ 6.86 2.56 6,593,832 $ 2.77 4.13
Summary of Stock-Based Compensation Expense	The following table summarizes stock-based compensation expense for the three and nine months ended September 30, 2018 and 2017: Three Months Ended September 30, Nine Months Ended September 30, 2018 2017 2018 2017 Research and development expenses Stock-based compensation $ 20,000 $ 179,000 $ 73,000 $ 255,000 General and administrative expenses Common stock issued for services - - 60,000 60,000 Stock-based compensation 75,000 127,000 214,000 354,000 $ 95,000 $ 306,000 $ 347,000 $ 669,000 Unrecognized expense at September 30, 2018 $ 68,000 Weighted average remaining years to vest 1.26
Warrants Issued in Conjunction with its Senior Convertible Debentures	The following table summarizes Ampio’s warrant activity: Number of Warrants Weighted Average Exercise Price Weighted Average Remaining Contractual Life Outstanding at December 31, 2017 13,332,243 $ 0.73 4.01 Warrants issued 20,000,000 $ 0.40 Warrants exercised (6,200,476 ) $ 0.50 Warrants expired (498,576 ) $ 3.24 Outstanding at September 30, 2018 26,633,191 $ 0.49 4.56
August 2018 warrants [Member]
Fair Value, Assets and Liabilities Measured on Nonrecurring Basis, Valuation Techniques	As of September 30, 2018, these warrants had a fair value of $8.7 million. Significant assumptions as of September 30, 2018 and at issuance were as follows: September 30, 2018 At Issuance Exercise Price $ 0.40 $ 0.40 Volatility 123.7 % 121.8 % Equivalent term (years) 4.87 5.00 Risk-free interest rate 2.94 % 2.75 % Number of shares 19,950,000 20,000,000
June 2017 warrants [Member]
Fair Value, Assets and Liabilities Measured on Nonrecurring Basis, Valuation Techniques	As of September 30, 2018, these warrants had a fair value of $2.4 million. Significant assumptions as of September 30, 2018 and at issuance were as follows: September 30, 2018 At Issuance Exercise Price $ 0.76 $ 0.76 Volatility 137.2 % 94.6 % Equivalent term (years) 3.67 5.00 Risk-free interest rate 2.90 % 1.71 % Number of shares 6,093,582 10,990,245
Warrant [Member]
Assumptions Used in Computing Fair Value of All Options Granted	Ampio has computed the fair value for options granted and modified during the period ended September 30, 2018, using the following assumptions: Expected volatility 100.66% - 127.60% Risk free interest rate 1.86% - 2.96% Expected term (years) 0.32 - 5.00 Dividend yield 0.0 %

Basis of Presentation - Additio

Basis of Presentation - Additional Information (Detail) $ in Millions	3 Months Ended
	Sep. 30, 2018USD ($)
Operating Lease, Payments	$ 2.1

Going Concern - Additional Info

Going Concern - Additional Information (Detail) - USD ($)	1 Months Ended			3 Months Ended		9 Months Ended
	Aug. 31, 2018	Jun. 30, 2017	Sep. 30, 2016	Sep. 30, 2018	Sep. 30, 2017	Sep. 30, 2018	Sep. 30, 2017	Dec. 31, 2017	Dec. 31, 2016
Net Income (Loss) Attributable to Parent				$ 5,801,220	$ (4,252,909)	$ 32,460,894	$ (8,765,673)
Net Cash Provided by (Used in) Operating Activities						(9,812,379)	(8,836,219)
Cash and Cash Equivalents, at Carrying Value				8,672,062	1,807,149	8,672,062	1,807,149	$ 8,209,071	$ 4,894,834
Stockholders' Equity Attributable to Parent				2,236,877		2,236,877		(34,176,885)
Retained Earnings (Accumulated Deficit)				(172,527,780)		(172,527,780)		$ (204,988,674)
Gain (Loss) on Derivative Instruments, Net, Pretax				7,744,708	(1,146,772)	41,110,851	2,092,994
Stock Issued During Period, Value, Warrants and Stock Options Exercised						3,600,000
Operating Expenses				$ 1,940,298	$ 3,106,137	8,646,767	10,861,753
Proceeds from Issuance of Common Stock	$ 8,000,000	$ 6,600,000	$ 3,750,000			$ 8,000,000	$ 6,594,148

Fixed Assets (Detail)

Fixed Assets (Detail) - USD ($)	9 Months Ended
	Sep. 30, 2018	Dec. 31, 2017
Property, Plant and Equipment [Line Items]
Less accumulated depreciation and amortization	$ (4,522,000)	$ (3,626,000)
Fixed assets, net	6,355,577	6,837,861
Manufacturing Facility [Member]
Property, Plant and Equipment [Line Items]
Fixed assets, gross	$ 3,197,000	2,773,000
Manufacturing Facility [Member] | Minimum [Member]
Property, Plant and Equipment [Line Items]
Estimated useful lives	3 years
Manufacturing Facility [Member] | Maximum [Member]
Property, Plant and Equipment [Line Items]
Estimated useful lives	8 years
Leasehold Improvements [Member]
Property, Plant and Equipment [Line Items]
Fixed assets, gross	$ 6,075,000	6,075,000
Estimated useful lives	10 years
Office Furniture And Equipment [Member]
Property, Plant and Equipment [Line Items]
Fixed assets, gross	$ 511,000	557,000
Office Furniture And Equipment [Member] | Minimum [Member]
Property, Plant and Equipment [Line Items]
Estimated useful lives	3 years
Office Furniture And Equipment [Member] | Maximum [Member]
Property, Plant and Equipment [Line Items]
Estimated useful lives	10 years
Lab Equipment [Member]
Property, Plant and Equipment [Line Items]
Fixed assets, gross	$ 1,095,000	$ 1,059,000
Lab Equipment [Member] | Minimum [Member]
Property, Plant and Equipment [Line Items]
Estimated useful lives	5 years
Lab Equipment [Member] | Maximum [Member]
Property, Plant and Equipment [Line Items]
Estimated useful lives	8 years

Fixed Assets -Depreciation and

Fixed Assets -Depreciation and Amortization Expense (Detail) - USD ($)	3 Months Ended		9 Months Ended
	Sep. 30, 2018	Sep. 30, 2017	Sep. 30, 2018	Sep. 30, 2017
Property, Plant and Equipment [Line Items]
Depreciation, Depletion and Amortization, Nonproduction	$ 347,000	$ 304,000	$ 968,000	$ 911,000

Fair Value Considerations - Fin

Fair Value Considerations - Financial Assets and Liabilities (Detail) - USD ($)	Sep. 30, 2018	Dec. 31, 2017
LIABILITIES
Warrant derivative liability	$ 11,120,000	$ 45,076,000
Fair Value, Inputs, Level 1 [Member]
LIABILITIES
Warrant derivative liability	0	0
Fair Value, Inputs, Level 2 [Member]
LIABILITIES
Warrant derivative liability	0	0
Fair Value, Inputs, Level 3 [Member]
LIABILITIES
Warrant derivative liability	$ 11,120,000	$ 45,076,000

Fair Value Considerations - Set

Fair Value Considerations - Sets Forth a Reconciliation of Changes (Detail)	9 Months Ended
	Sep. 30, 2018USD ($)
Fair Value, Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation [Line Items]
Balance as of December 31, 2017	$ 45,076,000
Warrants issuances	8,008,000
Warrants exercises	(13,925,000)
Change in fair value	(28,039,000)
Balance as of September 30, 2018	$ 11,120,000

Commitments and Contingencies -

Commitments and Contingencies - Additional Information (Detail) - USD ($)	9 Months Ended
	Sep. 30, 2018	Mar. 31, 2018	Dec. 31, 2013	Oct. 31, 2013
Commitments and Contingencies [Line Items]
Contractual obligation	$ 11,228,000
Newly Leased Office Space and Manufacturing Facility [Member]
Commitments and Contingencies [Line Items]
Lessee, Operating Lease, Term of Contract			125 months
Lease initial base rent per month	23,000
Total base rent over the term of the lease	3,300,000
Ampion Study Production [Member]
Commitments and Contingencies [Line Items]
Contractual obligation				$ 7,700,000
Other Commitment	$ 327,000
Biologics License Application BLA Consulting Services Agreement [Member]
Commitments and Contingencies [Line Items]
Contractual obligation		$ 1,200,000

Commitments and Contingencies_2

Commitments and Contingencies - Summary of Commitments and Contingencies (Detail)	Sep. 30, 2018USD ($)
Commitment And Contingencies [Line Items]
Total	$ 11,228,000
2,018	2,952,000
2,019	4,047,000
2,020	2,885,000
2,021	345,000
2,022	355,000
Thereafter	644,000
Ampion Supply Agreement [Member]
Commitment And Contingencies [Line Items]
Total	7,650,000
2,018	2,550,000
2,019	2,550,000
2,020	2,550,000
2,021	0
2,022	0
Thereafter	0
Biologics license application (BLA) consulting services [Member]
Commitment And Contingencies [Line Items]
Total	1,166,000
2,018	45,000
2,019	1,121,000
2,020	0
2,021	0
2,022	0
Thereafter	0
Clinical research and trial obligations [Member]
Commitment And Contingencies [Line Items]
Total	327,000
2,018	277,000
2,019	50,000
2,020	0
2,021	0
2,022	0
Thereafter	0
Facility lease [Member]
Commitment And Contingencies [Line Items]
Total	2,085,000
2,018	80,000
2,019	326,000
2,020	335,000
2,021	345,000
2,022	355,000
Thereafter	$ 644,000

Commitments and Contingencies_3

Commitments and Contingencies - Rent Expense (Detail) - USD ($)	3 Months Ended		9 Months Ended
	Sep. 30, 2018	Sep. 30, 2017	Sep. 30, 2018	Sep. 30, 2017
Commitment And Contingencies [Line Items]
Rent expense	$ 65,000	$ 65,000	$ 195,000	$ 195,000

Common Stock - Additional Infor

Common Stock - Additional Information (Detail) - USD ($)	1 Months Ended							3 Months Ended			9 Months Ended		12 Months Ended
	Aug. 31, 2018	Aug. 02, 2018	Jul. 31, 2018	Oct. 31, 2017	Jun. 30, 2017	Mar. 31, 2017	Sep. 30, 2016	Sep. 30, 2018	Sep. 30, 2017	Mar. 31, 2017	Sep. 30, 2018	Sep. 30, 2017	Dec. 31, 2017	Dec. 31, 2016	Mar. 27, 2017	Feb. 29, 2016
Components Of Common Stock [Line Items]
Common Stock, shares outstanding								106,591,516			106,591,516		80,060,345
Common Stock, shares authorized								200,000,000			200,000,000		200,000,000	200,000,000
Common Stock, par value								$ 0.0001			$ 0.0001		$ 0.0001	$ 0.0001
Preferred Stock, shares authorized								10,000,000			10,000,000		10,000,000
Preferred Stock, par value								$ 0.0001			$ 0.0001		$ 0.0001
Remaining common stocks and warrants under shelf registration								$ 78,700,000			$ 78,700,000
Maximum aggregate offering price of equity securities																$ 25,000,000
Percentage of commission		7.00%			8.00%
Stock Issued During Period, Shares, New Issues		20,000,000			11,000,000		5,000,000
Class of Warrant or Right, Number of Securities Called by Warrants or Rights		20,000,000	138,477		11,000,000
Class of Warrant or Right, Exercise Price of Warrants or Rights		$ 0.40			$ 0.76		$ 1							1
Proceeds from Issuance of Common Stock	$ 8,000,000				$ 6,600,000		$ 3,750,000				$ 8,000,000	$ 6,594,148
Combined Purchase Price, Per Share And Warrant					$ 0.60		$ 0.75
Share Based Compensation, Warrants Issued											20,000,000
Stock Issued During Period, Value, New Issues							$ 5,000,000				$ 0
Issuance Of Warrants Value							$ 4,100,000					4,600,000
Commission Of Gross Offering Proceeds		$ 560,000
Non Cash Charges		8,000,000
Payment of Financing and Stock Issuance Costs		$ 284,000
Gain (Loss) on Derivative Instruments, Net, Pretax								$ 7,744,708	$ (1,146,772)		41,110,851	2,092,994
Warrants and Rights Outstanding					$ 369,000
Payments of Stock Issuance Costs											$ 844,409	$ 812,288
Participation Rights Percentage					35.00%		30.00%
Combine Purchase Price Per share and Warrant		$ 0.40
Minimum [Member]
Components Of Common Stock [Line Items]
Class of Warrant or Right, Exercise Price of Warrants or Rights						$ 0.40				$ 0.40					$ 0.40
Maximum [Member]
Components Of Common Stock [Line Items]
Class of Warrant or Right, Exercise Price of Warrants or Rights						$ 1				$ 1					$ 1
Common Stock [Member]
Components Of Common Stock [Line Items]
Stock Issued During Period, Shares, New Issues			103,148								20,000,000
Stock Issued During Period, Value, New Issues											$ 2,000
Non Employee Directors [Member] | Common Stock [Member]
Components Of Common Stock [Line Items]
Issuance of common stock for services, shares											17,241	62,478
Issuance of common stock for services											$ 60,000	$ 60,000
Shelf Registration [Member]
Components Of Common Stock [Line Items]
Common stock and warrants						$ 100,000,000				$ 100,000,000
Common stock to be sold by directors and management in future public offerings						5,000,000
Stock Issued During Period, Value, New Issues							$ 5,000,000
Registered Direct Placement [Member]
Components Of Common Stock [Line Items]
Proceeds from Issuance of Common Stock											$ 3,400,000
Share Based Compensation, Warrants Issued											150,000
Stock Issued During Period, Value, New Issues											$ 5,000,000
Non Cash Charges											4,200,000
Gain (Loss) on Derivative Instruments, Net, Pretax										$ 1,100,000	$ 804,000
Placement Agent [Member]
Components Of Common Stock [Line Items]
Percentage of commission							6.00%
Class of Warrant or Right, Exercise Price of Warrants or Rights							$ 0.9375		$ 0.76			$ 0.76	$ 0.76	$ 0.9375
Share Based Compensation, Warrants Issued					879,000		150,000						879,000	150,000
Commission Of Gross Offering Proceeds					$ 533,000		$ 225,000
Payment of Financing and Stock Issuance Costs					$ 292,000		113,000
Warrants and Rights Outstanding							$ 89,000
Registered Direct Offering [Member]
Components Of Common Stock [Line Items]
Stock Issued During Period, Shares, New Issues				7,700,000
Proceeds from Issuance of Common Stock				$ 6,700,000
Combined Purchase Price, Per Share And Warrant				$ 0.875
Payments of Stock Issuance Costs				$ 490,000
Confidentially Marketed Public Offering [Member]
Components Of Common Stock [Line Items]
Class of Warrant or Right, Exercise Price of Warrants or Rights		$ 0.40
Gain (Loss) on Derivative Instruments, Net, Pretax		$ 853,000
Confidentially Marketed Public Offering [Member] | Warrant [Member]
Components Of Common Stock [Line Items]
Proceeds from Issuance of Common Stock	$ 7.2
Agreement [Member]
Components Of Common Stock [Line Items]
Percentage of commission																3.00%

Equity Instruments - Additional

Equity Instruments - Additional Information (Detail) - USD ($)	1 Months Ended						3 Months Ended	9 Months Ended		12 Months Ended
	Aug. 31, 2018	Aug. 02, 2018	Jul. 31, 2018	Jun. 30, 2017	Mar. 31, 2017	Sep. 30, 2016	Mar. 31, 2017	Sep. 30, 2018	Sep. 30, 2017	Dec. 31, 2017	Dec. 31, 2016	Mar. 27, 2017	Dec. 31, 2010
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Share Based Compensation, Warrants Issued								20,000,000
Stock Issued During Period, Shares, New Issues		20,000,000		11,000,000		5,000,000
Class of Warrant or Right, Exercise Price of Warrants or Rights		$ 0.40		$ 0.76		$ 1					$ 1
Warrants To Purchase Common Stock					5,000,000						5,000,000
Proceeds from Stock Options Exercised								$ 636,400
Number of Warrants, Expired					498,576			498,576
Class of Warrant or Right, Number of Securities Called by Warrants or Rights		20,000,000	138,477	11,000,000
August 2018 warrants [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Stock Issued During Period, Shares, New Issues								20,000,000
Class of Warrant or Right, Exercise Price of Warrants or Rights								$ 0.40
June 2017 warrants [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Stock Issued During Period, Shares, New Issues									11,000,000
Class of Warrant or Right, Exercise Price of Warrants or Rights									$ 0.76
Minimum [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Class of Warrant or Right, Exercise Price of Warrants or Rights					$ 0.40		$ 0.40					$ 0.40
Maximum [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Class of Warrant or Right, Exercise Price of Warrants or Rights					1		1					$ 1
Common Stock One [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercises in Period								409,666
Share-based Compensation Arrangements by Share-based Payment Award, Options, Exercises in Period, Weighted Average Exercise Price								$ 2.06
Waiver and Consent Agreement [Member] | Minimum [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Class of Warrant or Right, Exercise Price of Warrants or Rights					0.40		0.40
Waiver and Consent Agreement [Member] | Maximum [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Class of Warrant or Right, Exercise Price of Warrants or Rights					$ 1		$ 1
Placement Agent [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Share Based Compensation, Warrants Issued				879,000		150,000				879,000	150,000
Class of Warrant or Right, Exercise Price of Warrants or Rights						$ 0.9375			$ 0.76	$ 0.76	$ 0.9375
Share Vesting On Grant Date [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Share-based Compensation Arrangement by Share-based Payment Award, Options, Forfeitures in Period								3,334
Share-based Compensation Arrangement by Share-based Payment Award, Options, Forfeitures and Expirations in Period								355,000
Investor [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Class of Warrant or Right, Exercise Price of Warrants or Rights								$ 0.40		$ 0.76	$ 0.40
Proceeds from Stock Options Exercised								$ 3,000,000
Class of Warrant or Right, Number of Securities Called by Warrants or Rights								50,000		1,511,999	4,500,000
Warrant [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Derivative Liability								$ 11,100,000
Warrant [Member] | August 2018 warrants [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Share Based Compensation, Warrants Issued	20,000,000							19,950,000
Fair Value Adjustment of Warrants								$ 8,700,000
Warrant [Member] | June 2017 warrants [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Share Based Compensation, Warrants Issued				10,990,245				6,093,582
Fair Value Adjustment of Warrants								$ 2,400,000
Common Stock [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Stock Issued During Period, Shares, New Issues			103,148					20,000,000
Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercises in Period								348,783
Ampio [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Share-based Compensation Arrangement by Share-based Payment Award, Options, Forfeitures in Period								3,334
Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercises in Period								409,666
Share-based Compensation Arrangements by Share-based Payment Award, Options, Exercises in Period, Weighted Average Exercise Price								$ 2.06
Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Gross								115,000
Share-based Compensation Arrangements by Share-based Payment Award, Options, Grants in Period, Weighted Average Exercise Price								$ 0.51
Ampio March 2010 Stock Plan [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Shares of common stock reserved for issuance													11,700,000
Modified Outstanding Warrants [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Allocated Share-based Compensation Expense							$ 75,000
Modified Outstanding Warrants One [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Allocated Share-based Compensation Expense							$ 1,100,000

Equity Instruments - Stock Opti

Equity Instruments - Stock Option Activity (Detail) - USD ($)	9 Months Ended	12 Months Ended
	Sep. 30, 2018	Dec. 31, 2017
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Weighted Average Remaining Contractual Life, Outstanding		5 years 1 month 28 days
Aggregated Intrinsic Value, Outstanding	$ 7,784	$ 12,739,512
Aggregated Intrinsic Value, Exercisable	$ 7,411
Ampio [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Number of Options, Beginning Balance	7,247,165
Number of Options, Granted	115,000
Number of Options, Exercised	(409,666)
Number of Options, Forfeited	(3,334)
Number of Options, Expired or Cancelled	(355,333)
Number of Options, Ending Balance	6,593,832	7,247,165
Number of Options, Exercisable	6,242,164
Number of Options, Available for grant	3,198,478
Weighted Average Exercise Price, Beginning Balance	$ 2.87
Weighted Average Exercise Price, Granted	0.51
Weighted Average Exercise Price, Exercised	2.06
Weighted Average Exercise Price, Forfeited	1.02
Weighted Average Exercise Price, Expired or Cancelled	5.09
Weighted Average Exercise Price, Ending Balance	2.77	$ 2.87
Weighted Average Exercise Price, Exercisable	$ 2.88
Weighted Average Remaining Contractual Life, Outstanding	4 years 1 month 17 days
Weighted Average Remaining Contractual Life, Exercisable	3 years 10 months 20 days

Equity Instruments - Summary of

Equity Instruments - Summary of Stock Options Outstanding and Exercisable (Detail)	9 Months Ended
	Sep. 30, 2018$ / sharesshares
Share-based Compensation, Shares Authorized under Stock Option Plans, Exercise Price Range [Line Items]
Number of Options Outstanding | shares	6,593,832
Weighted Average Exercise Price | $ / shares	$ 2.77
Weighted Average Remaining Contractual Lives	4 years 1 month 17 days
$0.48 - $2.00[Member]
Share-based Compensation, Shares Authorized under Stock Option Plans, Exercise Price Range [Line Items]
Number of Options Outstanding | shares	3,083,554
Weighted Average Exercise Price | $ / shares	$ 0.89
Weighted Average Remaining Contractual Lives	5 years 3 months 11 days
$2.01 - $5.00 [Member]
Share-based Compensation, Shares Authorized under Stock Option Plans, Exercise Price Range [Line Items]
Number of Options Outstanding | shares	2,285,278
Weighted Average Exercise Price | $ / shares	$ 3.10
Weighted Average Remaining Contractual Lives	3 years 5 months 5 days
$5.01 - $8.93 [Member]
Share-based Compensation, Shares Authorized under Stock Option Plans, Exercise Price Range [Line Items]
Number of Options Outstanding | shares	1,225,000
Weighted Average Exercise Price | $ / shares	$ 6.86
Weighted Average Remaining Contractual Lives	2 years 6 months 22 days

Equity Instruments - Assumption

Equity Instruments - Assumptions Used in Computing Fair Value of All Options Granted (Detail)	9 Months Ended
	Sep. 30, 2018
Dividend yield	0.00%
Minimum [Member]
Expected volatility	100.66%
Risk free interest rate	1.86%
Expected term (years)	3 months 25 days
Maximum [Member]
Expected volatility	127.60%
Risk free interest rate	2.96%
Expected term (years)	5 years

Equity Instruments - Summary _2

Equity Instruments - Summary of Stock-Based Compensation Expense (Detail) - USD ($)	3 Months Ended		9 Months Ended
	Sep. 30, 2018	Sep. 30, 2017	Sep. 30, 2018	Sep. 30, 2017
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Unrecognized expense at June 30, 2018	$ 68,000
Weighted average remaining years to vest	1 year 3 months 4 days
Research and Development Expenses [Member] | Stock Based Compensation [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Stock-based compensation expenses	$ 20,000	$ 179,000	$ 73,000	$ 255,000
General and Administrative Expenses [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Stock-based compensation expenses	95,000	306,000	347,000	669,000
General and Administrative Expenses [Member] | Stock Based Compensation [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Stock-based compensation expenses	75,000	127,000	214,000	354,000
General and Administrative Expenses [Member] | Common Stock Issued for Services [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Stock-based compensation expenses	$ 0	$ 0	$ 60,000	$ 60,000

Equity Instruments - Assumpti_2

Equity Instruments - Assumptions for Warrants Issued (Detail) - $ / shares	1 Months Ended		9 Months Ended
	Aug. 31, 2018	Jun. 30, 2017	Sep. 30, 2018
Number of shares			20,000,000
Warrant [Member] | August 2018 warrants [Member]
Exercise price	$ 0.40		$ 0.40
Volatility	121.80%		123.70%
Equivalent term (years)	5 years		4 years 10 months 13 days
Risk-free interest rate	2.75%		2.94%
Number of shares	20,000,000		19,950,000
Warrant [Member] | June 2017 warrants [Member]
Exercise price		$ 0.76	$ 0.76
Volatility		94.60%	137.20%
Equivalent term (years)		5 years	3 years 8 months 1 day
Risk-free interest rate		1.71%	2.90%
Number of shares		10,990,245	6,093,582

Equity Instruments - Warrants I

Equity Instruments - Warrants Issued in Conjunction with its Senior Convertible Debentures (Detail) - $ / shares	1 Months Ended	9 Months Ended	12 Months Ended
	Mar. 31, 2017	Sep. 30, 2018	Dec. 31, 2017
Number of Warrants Outstanding
Number of Warrants Outstanding, Beginning Balance		13,332,243
Number of Warrants issued		20,000,000
Number of Warrants, exercised		(6,200,476)
Number of Warrants, Expired	(498,576)	(498,576)
Number of Warrants Outstanding, Ending Balance		26,633,191	13,332,243
Warrants, Weighted Average Exercise Price
Weighted Average Exercise Price, Outstanding Beginning Balance		$ 0.73
Weighted Average Exercise Price, issued		0.40
Weighted Average Exercise Price, Warrants exercised		0.50
Weighted Average Exercise Price, Warrants Expired		3.24
Weighted Average Exercise Price, Outstanding Ending Balance		$ 0.49	$ 0.73
Weighted Average Remaining Contractual Life
Weighted Average Remaining Contractual Life, Warrants Outstanding		4 years 6 months 22 days	4 years 4 days

Related Party Transactions - Ad

Related Party Transactions - Additional Information (Detail) - USD ($)	3 Months Ended	9 Months Ended
	Jun. 30, 2017	Sep. 30, 2018	Sep. 30, 2017
Trauma Research LLC [Member]
Related Party Transaction [Line Items]
Research and Development Expense	$ 252,000
AytuBioScienceInc [Member]
Related Party Transaction [Line Items]
Shared Overhead Cost		$ 0	$ 77,000

Subsequent Events - Additional

Subsequent Events - Additional Information (Detail) - USD ($)	1 Months Ended					9 Months Ended
	Nov. 14, 2018	Oct. 31, 2018	Aug. 31, 2018	Jun. 30, 2017	Sep. 30, 2016	Sep. 30, 2018	Sep. 30, 2017	Oct. 01, 2018	Aug. 02, 2018	Dec. 31, 2016
Subsequent Event [Line Items]
Proceeds from Issuance of Common Stock			$ 8,000,000	$ 6,600,000	$ 3,750,000	$ 8,000,000	$ 6,594,148
Class of Warrant or Right, Exercise Price of Warrants or Rights				$ 0.76	$ 1				$ 0.40	$ 1
Subsequent Event [Member]
Subsequent Event [Line Items]
Proceeds from Issuance of Common Stock	$ 50,000
Common Stock Issued Waraant Exercise	125,000
Class of Warrant or Right, Exercise Price of Warrants or Rights	$ 0.40
Option Repricing Description		44% above the closing price of the Company’s common stock on October 1, 2018 and 88% above the price per share of common stock sold in the Company’s recently completed public offering (not including the value of the accompanying warrants). “Relevant Options” are all outstanding stock options as of October 1, 2018 (vested or unvested) to acquire shares of the Company’s common stock that had exercise prices above $0.75 per share; provided, however, that the maximum dollar value of the repricing for any individual did not exceed $500,000 (with such value calculated by multiplying (i) the difference between the initial exercise price and $0.75 by (ii) the number of options being repriced). In conjunction with the repricing, the Compensation Committee determined to eliminate all outstanding accrued bonuses, which amount to approximately $813,000.
Subsequent Event [Member] | Option Repricing [Member]
Subsequent Event [Line Items]
Class of Warrant or Right, Exercise Price of Warrants or Rights								$ 0.75
Maximum Value Of Repricing For Individual		$ 500,000
Accrued Bonuses Discount								$ 813,000